TY - JOUR
T1 - Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC
AU - Travis, Ruth C.
AU - Allen, Naomi E.
AU - Appleby, Paul N.
AU - Price, Alison
AU - Kaaks, Rudolf
AU - Chang-Claude, Jenny
AU - Boeing, Heiner
AU - Aleksandrova, Krasimira
AU - Tjønneland, Anne
AU - Johnsen, Nina Føns
AU - Overvad, Kim
AU - Ramón Quirós, J.
AU - González, Carlos A.
AU - Molina-Montes, Esther
AU - Sánchez, Maria José
AU - Larrañaga, Nerea
AU - Castaño, José María Huerta
AU - Ardanaz, Eva
AU - Khaw, Kay Tee
AU - Wareham, Nick
AU - Trichopoulou, Antonia
AU - Karapetyan, Tina
AU - Rafnsson, Snorri Bjorn
AU - Palli, Domenico
AU - Krogh, Vittorio
AU - Tumino, Rosario
AU - Vineis, Paolo
AU - Bueno-De-Mesquita, H. Bas
AU - Stattin, Pär
AU - Johansson, Mattias
AU - Fedirko, Veronika
AU - Norat, Teresa
AU - Siddiq, Afshan
AU - Riboli, Elio
AU - Key, Timothy J.
PY - 2012/7
Y1 - 2012/7
N2 - Purpose: Data from prospective epidemiological studies in Asian populations and from experimental studies in animals and cell lines suggest a possible protective association between dietary isoflavones and the development of prostate cancer. We examined the association between circulating concentrations of genistein and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. Methods: Concentrations of the isoflavone genistein were measured in prediagnostic plasma samples for 1,605 prostate cancer cases and 1,697 matched control participants. Relative risks (RRs) for prostate cancer in relation to plasma concentrations of genistein were estimated by conditional logistic regression. Results: Plasma genistein concentrations were not associated with prostate cancer risk; the multivariate relative risk for men in the highest fifth of genistein compared with men in the lowest fifth was 1.00 (95 % confidence interval: 0.79, 1.27; p linear trend = 0.82). There was no evidence of heterogeneity in this association by age at blood collection, country of recruitment, or cancer stage or histological grade. Conclusion: Plasma genistein concentration was not associated with prostate cancer risk in this large cohort of European men.
AB - Purpose: Data from prospective epidemiological studies in Asian populations and from experimental studies in animals and cell lines suggest a possible protective association between dietary isoflavones and the development of prostate cancer. We examined the association between circulating concentrations of genistein and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. Methods: Concentrations of the isoflavone genistein were measured in prediagnostic plasma samples for 1,605 prostate cancer cases and 1,697 matched control participants. Relative risks (RRs) for prostate cancer in relation to plasma concentrations of genistein were estimated by conditional logistic regression. Results: Plasma genistein concentrations were not associated with prostate cancer risk; the multivariate relative risk for men in the highest fifth of genistein compared with men in the lowest fifth was 1.00 (95 % confidence interval: 0.79, 1.27; p linear trend = 0.82). There was no evidence of heterogeneity in this association by age at blood collection, country of recruitment, or cancer stage or histological grade. Conclusion: Plasma genistein concentration was not associated with prostate cancer risk in this large cohort of European men.
KW - Genistein
KW - Isoflavone
KW - Phyto-estrogen
KW - Plasma
KW - Prospective
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84862486948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862486948&partnerID=8YFLogxK
U2 - 10.1007/s10552-012-9985-y
DO - 10.1007/s10552-012-9985-y
M3 - Article
C2 - 22674291
AN - SCOPUS:84862486948
VL - 23
SP - 1163
EP - 1171
JO - Cancer Causes and Control
JF - Cancer Causes and Control
SN - 0957-5243
IS - 7
ER -